Want to see AU:CUV full AI Analyst Report?
Top Page
Clinuvel Pharmaceuticals
(Sydney:CUV)
Select Model
Select Model
Rating:73Outperform
Price Target:
AU$9.50
▼(-10.38% Downside)
Action:Reiterated
Date:08/30/26
The score is driven primarily by strong financial fundamentals (low leverage, sustained profitability, and robust cash generation) and a generally positive earnings-call outlook supported by high cash reserves and identifiable catalysts. These strengths are tempered by weak technicals (price below key moving averages with bearish momentum) and recent financial softening signals (2026 revenue decline, margin reset, and weaker free cash flow growth). Valuation is supportive via a modest P/E, though the dividend yield provides little additional buffer.
Positive Factors
Debt-free balance sheet and growing liquidity
Minimal leverage and substantial cash reserves reduce financial risk, support continued investment in clinical and manufacturing capabilities, and provide funding flexibility without near-term dependence on debt or equity issuance.
Negative Factors
Revenue decline and gross-margin reset
The return to negative revenue growth and weaker gross margin may indicate pricing, product-mix, or cost pressure. If sustained, these trends could reduce operating leverage and weaken the earnings power supporting future investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet and growing liquidity
Minimal leverage and substantial cash reserves reduce financial risk, support continued investment in clinical and manufacturing capabilities, and provide funding flexibility without near-term dependence on debt or equity issuance.
Read all positive factors
Clinuvel Pharmaceuticals (CUV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$427.12M
Dividend Yield0.59%
Average Volume (3M)97.23K
Price to Earnings (P/E)12.5
Beta (1Y)0.61
Revenue Growth-1.05%
EPS Growth-6.74%
CountryAU
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.68
Shares Outstanding50,427,900
10 Day Avg. Volume118,433
30 Day Avg. Volume97,231
Financial Highlights & Ratios
PEG Ratio-2.72
Price to Book (P/B)1.88
Price to Sales (P/S)5.45
P/FCF Ratio14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$17.25Price Target Upside62.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.73
Revenue Forecast (FY)AU$104.30M
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Company Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, t...
How the Company Makes Money
Clinuvel primarily makes money by selling its prescription pharmaceutical product SCENESSE® (afamelanotide) in markets where it has regulatory approval. Revenue is generated from commercial supply of SCENESSE through specialty distribution and rei...
Clinuvel Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 23, 2027
Earnings Call Sentiment Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.Positive Updates
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Negative Updates
Overall Expense Growth
Total expenses increased 22% for the period, driven by the company’s expansion initiatives and higher operating activity, resulting in lower net profit relative to prior periods.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Read all positive updates
Company Guidance
Guidance from the call was that CLINUVEL will continue a controlled expansion while tightly managing costs, with full‑year operating expense guidance of about A$55–58m (ex‑capex); H1 sales rose 4% YoY to just under A$37m (the highest H1 on record), interest income was A$5.3m (up 14%), cash increased by A$9m to A$233m, net assets rose A$8.2m to ~A$250m, the company remains debt‑free for a 21st year and has delivered its 20th consecutive profit. Management flagged expense drivers (total expenses +22%: personnel +16%, commercial distribution +42%, finance/legal +47%, other R&D +191%), lower non‑cash and share‑based charges (share plan now 1‑year), term deposits average ~300 days at ~4.5% yield, revenue split ~53% U.S./47% RoW, <5% U.S. patients on Medicaid, and near‑term catalysts include CUV105 topline in H2 2026, start of CUV107, peptide preclinical data H2 2026 and the ADR/NASDAQ uplift pending SEC responses.Clinuvel Pharmaceuticals Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 94.02M | 95.02M | 88.18M | 78.32M | 65.72M |
| Gross Profit | 40.53M | 79.14M | 80.45M | 50.59M | 46.62M |
| EBITDA | 40.53M | 57.20M | 56.28M | 46.37M | 35.08M |
| Net Income | 33.92M | 36.17M | 35.64M | 30.60M | 20.88M |
Balance Sheet | |||||
| Total Assets | 296.15M | 271.75M | 231.12M | 194.52M | 144.81M |
| Cash, Cash Equivalents and Short-Term Investments | 252.06M | 224.11M | 183.87M | 156.81M | 121.51M |
| Total Debt | 1.94M | 528.53K | 879.78K | 999.87K | 1.26M |
| Total Liabilities | 23.27M | 30.94M | 28.11M | 29.89M | 19.25M |
| Stockholders Equity | 272.88M | 240.81M | 203.01M | 164.63M | 125.56M |
Cash Flow | |||||
| Free Cash Flow | 35.31M | 40.80M | 31.48M | 35.88M | 39.44M |
| Operating Cash Flow | 36.91M | 41.10M | 37.05M | 36.91M | 39.87M |
| Investing Cash Flow | -39.12M | -47.72M | -29.03M | -1.03M | -434.44K |
| Financing Cash Flow | -2.75M | -2.94M | -3.57M | -2.24M | -1.50M |
Clinuvel Pharmaceuticals Technical Analysis
Negative
10.60
Price Trends
9.94
Negative
9.56
Negative
10.43
Negative
Market Momentum
-0.02
Positive
33.11
Neutral
31.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CUV, the sentiment is Negative. The current price of 10.6 is above the 20-day moving average (MA) of 9.76, above the 50-day MA of 9.94, and above the 200-day MA of 10.43, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.11 is Neutral, neither overbought nor oversold. The STOCH value of 31.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CUV.
Clinuvel Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$427.12M | 12.46 | 13.29% | 0.50% | -1.05% | -6.74% | |
65 Neutral | AU$77.52M | 21.12 | 46.74% | ― | 29.68% | 1520.00% | |
54 Neutral | AU$2.21B | -26.63 | -30.03% | ― | ― | 39.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$341.09M | -41.81 | -15.96% | ― | 145.32% | 25.75% | |
47 Neutral | AU$57.47M | -0.65 | -131.13% | ― | 499.47% | 31.20% | |
46 Neutral | AU$6.19M | -7.50 | -45.29% | ― | 290.25% | 92.05% |
* Healthcare Sector Average
AU:CUV
Clinuvel Pharmaceuticals
8.47
-2.20
-20.60%
AU:ACR
Acrux
0.01
>-0.01
-33.33%
AU:SPL
Starpharma Holdings Limited
0.72
0.60
516.38%
AU:PYC
PYC Therapeutics Limited
2.25
1.04
86.57%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.52%
AU:BIO
Biome Australia Ltd
0.34
-0.17
-33.33%
Clinuvel Pharmaceuticals Corporate Events
Clinuvel Weighs Nasdaq-Only Listing as Headquarters Shift to U.S.
Aug 27, 2026
Clinuvel Pharmaceuticals’ board is evaluating a restructuring that would shift the group’s holding company offshore, list all ordinary shares on Nasdaq and delist from the Australian Securities Exchange and Frankfurt’s Börse...
Clinuvel Flags Key Risks as It Builds U.S.-Led Expansion
Aug 27, 2026
Clinuvel Pharmaceuticals has outlined its risk landscape as it prepares for expanded operations, including a stated focus on the U.S. market supported by its existing global foundation. The group highlights exposure to competition for its lead pro...
Clinuvel Confirms ASX Governance Compliance With 2026 Appendix 4G Filing
Aug 27, 2026
Clinuvel Pharmaceuticals has lodged its Appendix 4G with the ASX for the financial year ended 30 June 2026, confirming that its corporate governance statement is current as at 27 August 2026 and available on its website. The filing outlines that C...
Clinuvel Affirms ASX Governance Compliance and Highlights Diversity Gains
Aug 27, 2026
Clinuvel Pharmaceuticals has released its corporate governance statement for the year to 30 June 2026, confirming full compliance with the Australian Securities Exchange Corporate Governance Council’s 4th edition principles and recommendatio...
Clinuvel Declares AUD 0.05 Dividend for FY2026
Aug 27, 2026
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code CUV, with ordinary fully paid shares as its primary security. The company operates in the pharmaceuticals industry, focusing on the develo...
Clinuvel Leverages Decade of Profits to Fund U.S. Expansion Despite Flat FY2026 Revenue
Aug 27, 2026
Clinuvel Pharmaceuticals reported its tenth consecutive annual profit for the year ended 30 June 2026, supported by record SCENESSE treatment volumes and steady operating expenses. Revenue from ordinary activities slipped 1% to A$94.0 million, whi...
Clinuvel Sets Investor Webinar to Unveil 2026 Annual Results
Aug 20, 2026
Clinuvel Pharmaceuticals will release its annual financial results for the year ended 30 June 2026 on 27 August, accompanied by an investor and analyst webinar later that day. The online event, scheduled for 18:00 to 18:30 AEST, will allow partici...
Clinuvel Advances VLRX-L Controlled-Release Injectable Peptide Platform
Aug 11, 2026
Clinuvel Pharmaceuticals has reported progress on its VLRX-L controlled-release injectable liquid peptide platform, narrowing four preclinical formulations down to a lead candidate with a superior release profile. The optimized liquid formulation ...
Clinuvel steps up vitiligo push as SCENESSE data and North American rollout near
Jul 29, 2026
Clinuvel Pharmaceuticals has provided a commercial update on the emerging vitiligo treatment landscape, contrasting the longstanding narrowband UVB standard of care and newer topical and systemic JAK inhibitors with its SCENESSE therapy. The compa...
Clinuvel maps SCENESSE’s path in vitiligo with new Phase III trial
Jul 27, 2026
Clinuvel Pharmaceuticals has outlined the clinical and regulatory pathway to develop SCENESSE with narrowband UVB phototherapy as a treatment for vitiligo in patients with darker skin types. The company is completing its first late-stage vitiligo ...
Clinuvel Pharmaceuticals Reports Lapse of Performance Rights
Jul 26, 2026
Clinuvel Pharmaceuticals has notified the market of the cessation of 124,153 performance rights trading under ASX code CUVAK. The rights lapsed on 24 July 2026 after the specified performance conditions were not met or became incapable of being sa...
Clinuvel shifts headquarters to U.S. in strategic overhaul
Jul 22, 2026
Clinuvel Pharmaceuticals will relocate its corporate headquarters and key functions to the U.S. from 1 January 2027, in a strategic reorganisation aimed at strengthening regulatory engagement and commercial partnerships. The move accompanies a 10%...
Clinuvel Starts Trading Level II ADS on Nasdaq Under CUVL
Jul 21, 2026
Clinuvel Pharmaceuticals has expanded its U.S. market presence by commencing trading of its American Depositary Shares on the Nasdaq under the ticker CUVL, completing the move of its depositary program from a Level I ADR to a Level II ADS structur...
Clinuvel wins Health Canada approval for rare‑disease drug SCENESSE
Jul 12, 2026
Clinuvel Pharmaceuticals has secured Health Canada’s Notice of Compliance for SCENESSE, its afamelanotide implant, approving the drug to prevent phototoxic reactions in adults with erythropoietic protoporphyria, a rare metabolic disorder cau...
Clinuvel Extends CEO’s Term to 2029 as Board Backs Ambitious Expansion Plan
Jul 2, 2026
Clinuvel Pharmaceuticals has extended the employment agreement of CEO and managing director Dr Philippe Wolgen through 30 June 2029, keeping his fixed and short‑term remuneration unchanged while removing retention payments and long‑ter...
Clinuvel Files 20-F as It Pursues Nasdaq ADS Uplisting
Jun 16, 2026
Clinuvel Pharmaceuticals has publicly filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission as it seeks to upgrade its existing over-the-counter American Depositary Receipt program to a Level II American Deposit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.